Overview

"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine a preventative dose of study drug, Arixtra® for patients with kidney disease. We will measure the blood levels of Arixtra® in patients with kidney disease and develop guidelines for dosing.
Phase:
Phase 1
Details
Lead Sponsor:
Duke University
Collaborator:
GlaxoSmithKline
Treatments:
Fondaparinux
PENTA